Alzheimer's drug Leqembi promises to give patients more time, but they face a long road to treatment

Leqembi’s rollout has been slowed by bottlenecks related to reimbursement uncertainties, diagnostic test requirements and regular brain scans, among others.
source
Sponsor:News technical sponsor
Sponsor:News AI sponsor
Sponsor: AI sponsor
Sponsor: AI sponsor

Leave a Comment

Vélemény, hozzászólás?

Az e-mail címet nem tesszük közzé. A kötelező mezőket * karakterrel jelöltük